![Jennifer Champoux](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jennifer Champoux
Geschäftsführer bei MONTE ROSA THERAPEUTICS, INC.
Vermögen: 809 999 $ am 31.05.2024
Aktive Positionen von Jennifer Champoux
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MONTE ROSA THERAPEUTICS, INC. | Geschäftsführer | 01.03.2021 | - |
Personalreferent | 01.03.2021 | 28.05.2024 |
Karriereverlauf von Jennifer Champoux
Ehemalige bekannte Positionen von Jennifer Champoux
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - | - |
Ausbildung von Jennifer Champoux
Indiana University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Chief Operating Officer | 1 |
Human Resources Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MONTE ROSA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Börse
- Insiders
- Jennifer Champoux
- Erfahrung